Janssen-developed clinical trials tech available for industry use
The new platform features four modules including, communication, adherence, label, and tracking
The approach was developed by Janssen Research & Development as part of its integrated Smart Trial and Engagement Platform (iSTEP) initiative and will be made available for industry-use via Tata Consultancy Services (TCS) under the name Connected Clinical Trials (CCT).
“Drug accountability and medication management are the most complex elements of a clinical trial. CCT automates this entire process and thereby removes guesswork from the clinical trial,” a TCS spokesperson told Outsourcing-Pharma.com.
“Moreover, CCT leverages a powerful device data acquisition and analytical framework that helps a clinical trial benefit from a variety of devices on a single platform. Each trial is unique in itself and CCT helps study teams flexibly manage variation across trials through extensive configuration capability.”
The platform has been tested and proven in a live set-up at TCS' User Experience labs with global patient and site advisory boards in collaboration with the Center for Information and Study on Clinical Research Participation (CISCRP).
Additionally, Janssen has conducted a technical pilot and is working with health authorities and ethics committees to implement a pilot assessment of the technology in a clinical trial by the end of 2017.
Janssen plans to gradually implement iSTEP into clinical trials in its portfolio, according to the company.
